Latest Product Launches News

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

PEXA has achieved a crucial regulatory milestone with FCA approval to operate as an Authorised Payment Institution in the UK, paving the way for its Sale & Purchase product launch later this year.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.

Aeeris Ltd delivered solid Q3 FY2025 results, driven by strong recurring revenue growth, a successful new product launch, and strategic moves to internalise key forecasting capabilities.

Knosys Limited reports a record Annual Recurring Revenue run rate of $9.8 million, driven by strong enterprise renewals and new customer wins, alongside the launch of its next-generation Libero library app and upgraded LMS.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

DroneShield Limited has reported a record-breaking first quarter with $33.5 million in revenue, more than doubling year-over-year, supported by a robust $94.4 million in committed purchase orders and a burgeoning SaaS segment. The company’s expansive $1.6 billion sales pipeline and strong cash position set the stage for accelerated growth in the counter-unmanned systems market.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.